• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Surgalign Announces Appointment of David Lyle as Chief Financial Officer

    3/7/22 9:00:00 AM ET
    $SRGA
    Industrial Specialties
    Health Care
    Get the next $SRGA alert in real time by email

    DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA) ("Surgalign"), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately.

    "David brings a wealth of experience in helping to guide the growth of technologies to Surgalign at an important and exciting inflection point of the company's evolution," said Terry Rich, Surgalign's president and chief executive officer. "David is joining Surgalign at a critical time as we transition to the early commercial stage of our HOLO AI technology platform, with recent FDA clearance of our HOLO Portal™ surgical guidance system. We believe David's extensive financial acumen, corporate development successes, and experience launching novel technologies will be immediately impactful, and on behalf of our employees and the board of directors I would like to warmly welcome him to our team."

    Mr. Lyle brings more than two decades of financial leadership experience within the technology sector to Surgalign. He has an established track record in successfully scaling high growth technology companies, having served in leadership roles in both public and private organizations. Prior to joining Surgalign, Mr. Lyle was the CFO of Airgain, a publicly traded wireless communications systems company. Prior to joining Airgain, Mr. Lyle was the CFO of Sunniva, Inc., and before Sunniva, he was CFO at Maxwell Technologies, Inc. for four years, which was acquired by Tesla in 2019. He also served as the CFO of Entropic Communications, Inc., which was acquired in 2015 by MaxLinear. Prior to Entropic, he served as the CFO of RF Magic, acquired by Entropic in 2007, Zyray Wireless, acquired by Broadcom in 2004, and Mobilian, acquired by Intel in 2003. Mr. Lyle also has prior work experience in the commercial banking industry. He holds a Bachelor of Science in Business Administration from University of Southern California, a Master of International Management from the Thunderbird School of Global Management, and a Master of Business Administration from Arizona State University.

    "I'm thrilled to be joining Surgalign as they work to bring HOLO technology and its tremendous potential to the market," said Mr. Lyle. "Machine learning and artificial intelligence have the ability to revolutionize the way surgery is performed and ultimately the way patients are treated. The company has made significant progress with the early development of the platform, and I look forward to building on that momentum in the future."

    About Surgalign Holdings, Inc.

    Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company is building technologies physicians and other health providers will look to for what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland and Wurmlingen, Germany.

    Forward Looking Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting Surgalign's website at www.surgalign.com or the SEC's website at www.sec.gov.

    Investor and Media Contact:

    Mike Vallie

    [email protected]

    +1 443 213 0499



    Primary Logo

    Get the next $SRGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRGA

    DatePrice TargetRatingAnalyst
    9/28/2021$1.50Buy → Hold
    Craig Hallum
    More analyst ratings

    $SRGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Surgalign Holdings downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50

      9/28/21 7:57:45 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • BTIG Research initiated coverage on Surgalign Holdings with a new price target

      BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00

      2/3/21 7:33:38 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • BTIG Research initiated coverage on Surgalign

      BTIG Research initiated coverage of Surgalign with a rating of Buy

      2/3/21 7:28:58 AM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Surgalign Holdings Inc.

      15-12G - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      11/13/23 4:08:28 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Surgalign Holdings Inc.

      EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      10/10/23 12:15:07 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Surgalign Holdings Inc.

      EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      10/10/23 12:15:09 AM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing

      DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code, the Company's securities will be delisted from The Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. As previously announced, Surgalign entered into an asset purchase agreement to

      6/23/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy Code

      DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) ("Surgalign" or the "Company") a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. ("Xtant") for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain o

      6/20/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education Resources

      Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery ("ISASS") and Medical Education Resources. This three-day event will take place June 1-3, 2023 at the Marriott Marquis in San Francisco, CA. The International Society for the Advancement of Spine Surgery i

      5/23/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Lyle David covered exercise/tax liability with 1,329 shares, decreasing direct ownership by 2% to 83,307 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      9/18/23 11:47:26 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form 4: Amoruso Paolo covered exercise/tax liability with 2,191 shares, decreasing direct ownership by 7% to 28,809 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      9/5/23 10:20:10 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form 4: Thunander Christopher covered exercise/tax liability with 2,295 shares, decreasing direct ownership by 8% to 26,039 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      8/16/23 5:36:00 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary

      DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022. Commenting on today's appointment, Terry Rich, President and Chief Executive Officer of Surgalign stated, "Paolo has been an invaluable member of our team since taking on the role of Interim General Counsel just a few months ago. He has quickly immersed

      8/4/22 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Announces Appointment of David Lyle as Chief Financial Officer

      DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA) ("Surgalign"), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. "David brings a wealth of experience in helping to guide the growth of technologies to Surgalign at an important and exciting inflection point of the company's evolution," said Terry Rich, Surgalign's president and chief executive officer. "David is joining Surgalign at a critical time as we transition to the early commercial stage of our HOLO AI technology platform, w

      3/7/22 9:00:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Anika Appoints Sheryl Conley to Board of Directors

      BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management

      11/1/21 9:00:00 AM ET
      $ANIK
      $SRGA
      $STIM
      Medical/Dental Instruments
      Health Care
      Industrial Specialties

    $SRGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Surgalign Holdings Inc. (Amendment)

      SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/14/24 2:57:21 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Surgalign Holdings Inc.

      SC 13G - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/14/23 1:32:27 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Surgalign Holdings Inc. (Amendment)

      SC 13D/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/4/22 3:09:26 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Financials

    Live finance-specific insights

    See more
    • Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023

      DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available

      5/4/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million

      Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, Mont. and DEERFIELD, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, and Surgalign Holdings, Inc., (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered

      3/1/23 9:15:00 AM ET
      $SRGA
      $XTNT
      Industrial Specialties
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Surgalign Announces Third Quarter 2022 Results and Provides Update on Business Operations and Financial Outlook

      DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022. 2022 Third Quarter Corporate Highlights: Two new clinical sites in Ohio utilize the HOLO PortalTM surgical guidance system.FDA 510(k) clearance of the Cortera™ Spinal Fixation System, the first organically designed product by Surgalign.Expansion of the Fortilink® product portfolio with TiPlus™ technology products.Settlements with Resolve Surgical Technologies and RTI Surgical, Inc., and with

      11/2/22 4:01:00 PM ET
      $SRGA
      Industrial Specialties
      Health Care